PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 50,87 | 50,87 | 2024-04-03 |
| Vict Th Engwalls Stiftelse | 2,30 | 2,30 | 2023-12-27 |
| Avanza Pension | 1,67 | 1,67 | 2023-12-27 |
| Arne Arvidsson | 1,44 | 1,44 | 2023-12-27 |
| Nordnet Pensionsförsäkring | 0,94 | 0,94 | 2023-12-27 |
| Staffan Engelbert Bodén | 0,60 | 0,60 | 2023-12-27 |
| Henrik Skog | 0,57 | 0,57 | 2023-12-27 |
| Merrick Lee Tabor | 0,54 | 0,54 | 2023-12-27 |
| Mats Andersson | 0,52 | 0,52 | 2021-12-31 |
| Arne Skogvall | 0,52 | 0,52 | 2023-12-27 |
2024-05-16 Delårsrapport 2024-Q1
2024-08-15 Delårsrapport 2024-Q2
2024-11-21 Delårsrapport 2024-Q3
2025-02-20 Bokslutskommuniké 2024
